Lumos Pharma Inc LUMO:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 08/05/22 EDT
8.86quote price arrow up+0.43 (+5.10%)
Volume
200
Close
8.43quote price arrow down-0.12 (-1.40%)
Volume
1,949
52 week range
6.15 - 11.52
Loading...
  • Open8.63
  • Day High8.63
  • Day Low8.43
  • Prev Close8.55
  • 52 Week High11.52
  • 52 Week High Date09/02/21
  • 52 Week Low6.15
  • 52 Week Low Date01/21/22

Key Stats

  • Market Cap70.56M
  • Shares Out8.37M
  • 10 Day Average Volume0.01M
  • Dividend-
  • Dividend Yield-
  • Beta1.23
  • YTD % Change21.65

KEY STATS

  • Open8.63
  • Day High8.63
  • Day Low8.43
  • Prev Close8.55
  • 52 Week High11.52
  • 52 Week High Date09/02/21
  • 52 Week Low6.15
  • 52 Week Low Date01/21/22
  • Market Cap70.56M
  • Shares Out8.37M
  • 10 Day Average Volume0.01M
  • Dividend-
  • Dividend Yield-
  • Beta1.23
  • YTD % Change21.65

RATIOS/PROFITABILITY

  • EPS (TTM)-3.49
  • P/E (TTM)-2.42
  • Fwd P/E (NTM)-2.15
  • EBITDA (TTM)-30.346M
  • ROE (TTM)-30.94%
  • Revenue (TTM)340,000.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-8,656.60%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/09/2022
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Lumos Pharma Inc

There is no recent news for this security.

Profile

MORE
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, acquiring, developing, and commercializing products and therapies for people with rare diseases. Its lead product candidate is LUM-201, a therapy for pediatric growth hormone deficiency (PGHD) and other rare endocrine disorders. LUM-201 stimulates growth hormone (GH) through the GH secretagogue receptor. Its product provides a differentiated mechanism of action to treat...
Richard Hawkins
Chairman of the Board, Chief Executive Officer
John McKew Ph.D.
President, Chief Operating Officer, Chief Scientific Officer
Lori Lawley CPA
Chief Financial Officer, Principal Accounting Officer
Bradley Powers
General Counsel
Address
4200 MARATHON BLVD., SUITE 200
Austin, TX
78756
United States

Top Peers

SYMBOLLASTCHG%CHG
ANEB
Anebulo Pharmaceuticals Inc
4.24+0.23+5.74%
AKTX
Akari Therapeutics PLC
1.44+0.03+2.13%
EVAX
Evaxion Biotech A/S
3.09+0.12+4.04%
GNPX
Genprex Inc
1.43+0.03+2.14%
GMTX
Gemini Therapeutics Inc
1.56-0.02-1.27%